Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: A systematic review

PharmacoEconomics

Volumn 30, Issue 1, 2012, Pages 17-34

  Bongers, Mathilda L ^a   Coupé, Veerle M H ^a   Jansma, Elise P ^b   Smit, Egbert F ^a   Uyl De Groot, Carin A ^a,c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO;

ADVANCED CANCER; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; HUMAN; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; LUNG NEOPLASMS;

EID: 83455172451     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11595000-000000000-00000     Document Type: Review

References (45)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008 Mar; 58 (2): 71-96
2. National Institute for Health and Clinical Excellence. Lung cancer: the diagnosis and treatment of lung cancer. London: NICE, 2011 Apr
3. Integraal Kankercentrum Nederland. Non-small-cell lung cancer: Dutch guidelines [in Dutch]. Utrecht: IKNL, 2011 [online]. Available from URL: http://www.oncoline.nl/richtlijn/item/index.php?pagina=/richtlijn/item/pagina. php& richtlijn-id=799 [Accessed 2011 May 22]
4. Goffin J, Lacchetti C, Ellis PM, et al. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol 2010 Feb; 5 (2): 260-74
5. Pompen M, Gok M, Novak A, et al. Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in the Netherlands. Lung Cancer 2009; 64 (1): 110-6
6. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996; 313: 275-83 (Pubitemid 26254740)
7. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. Cochrane Collaboration, 2011 Mar [online]. Available from URL: http://www.cochrane-handbook.org [Accessed 2010 Oct 11]
8. Philips Z, Ginnelly L, Sculpher M, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004; 8 (36): iii-iv, ix-xi, 1-158
9. Bradbury PA, Tu D, Seymour L, et al. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. J Natl Cancer Inst 2010 Mar 3; 102 (5): 298-306
10. Carlson JJ, Reyes C, Oestreicher N, et al. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer 2008 Sep; 61 (3): 405-15
11. Holmes J, Dunlop D, Hemmett L, et al. A cost-effectiveness analysis of docetaxel in the second-line treatment of nonsmall cell lung cancer. Pharmacoeconomics 2004; 22 (9): 581-9 (Pubitemid 38943103)
12. Klein R, Muehlenbein C, Liepa AM, et al. Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 2009 Nov; 4 (11): 1404-14
13. Klein R, Wielage R, Muehlenbein C, et al. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 2010 Aug; 5 (8): 1263-72
14. Lees M, Aristides M, Maniadakis N, et al. Economic evaluation of gemcitabine alone and in combination with cisplatin in the treatment of nonsmall cell lung cancer. Pharmacoeconomics 2002; 20 (5): 325-37 (Pubitemid 34569366)
15. Leighl NB, Shepherd FA, Kwong R, et al. Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 2002 Mar 1; 20 (5): 1344-52 (Pubitemid 34177441)
16. Lewis G, Peake M, Aultman R, et al. Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom. J Int Med Res 2010 Jan; 38 (1): 9-21
17. Asukai Y, Valladares A, Camps C, et al. Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population. BMC Cancer 2010 Jan; 10: 26
18. Neymark N, Lianes P, Smit EF, et al. Economic evaluation of three two-drug chemotherapy regimens in advanced nonsmall- cell lung cancer. Pharmacoeconomics 2005; 23 (11): 1155-66 (Pubitemid 41633404)
19. Clegg A, Scott DA, Sidhu M, et al. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in nonsmall- cell lung cancer. Health Technol Assess 2001; 5 (32): 1-195
20. Dranitsaris G, Cottrell W, Evans WK. Cost-effectiveness of chemotherapy for nonsmall-cell lung cancer. Curr Opin Oncol 2002 Jul; 14 (4): 375-83 (Pubitemid 34747970)
21. Carlson JJ, Veenstra DL, Ramsey SD. Pharmacoeconomic evaluations in the treatment of non-small cell lung cancer. Drugs 2008; 68 (8): 1105-13 (Pubitemid 351693678)
22. Chouaid C, Atsou K, Hejblum G, et al. Economics of treatments for non-small cell lung cancer. Pharmacoeconomics 2009; 27 (2): 113-25
23. Carlson JJ. Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidence. Expert Rev Pharmacoecon Outcomes Res 2009 Oct; 9 (5): 409-16
24. Lyseng-Williamson KA. Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer. Pharmacoeconomics 2010; 28 (1): 75-92
25. Maniadakis N, Fragoulakis V, Pallis A, et al. Economic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in Greece. Lung Cancer 2007 Nov; 58 (2): 275-81 (Pubitemid 47520631)
26. Smit EF, van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975. J Clin Oncol 2003 Nov 1; 21 (21): 3909-17 (Pubitemid 46606203)
27. Comella P, Frasci G, Panza N, et al. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol 2000 Apr; 18 (7): 1451-7 (Pubitemid 30205390)
28. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002 Jan 10; 346 (2): 92-8 (Pubitemid 34438899)
29. Georgoulias V, Papadakis E, Alexopoulos A, et al. Platinum- based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 2001 May 12; 357 (9267): 1478-84 (Pubitemid 32488857)
30. Cleemput I, Neyt M, Thiry N, et al. Threshold values for cost-effectiveness in health care. Brussels: KCE, 2008. Report no. 100C
31. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced- stage non-small-cell lung cancer. J Clin Oncol 2008 Jul 20; 26 (21): 3543-51
32. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000 May; 18 (10): 2095-103 (Pubitemid 30324363)
33. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004 May 1; 22 (9): 1589-97 (Pubitemid 41079796)
34. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005 Jul 14; 353 (2): 123-32 (Pubitemid 41058344)
35. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000 Jun; 18 (12): 2354-62 (Pubitemid 30415821)
36. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press, 2005
37. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009 Sep 3; 361 (10): 947-57
38. Chouaid C, Monnet I, Robinet G, et al. Economic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based analysis. Curr Med Res Opin 2007 Jul; 23 (7): 1509-15 (Pubitemid 47122159)
39. Azzoli CG, Baker Jr S, Temin S, et al. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009 Dec 20; 27 (36): 6251-66
40. Bradley CJ, Yabroff KR, Dahman B, et al. Productivity costs of cancer mortality in the United States: 2000-2020. J Natl Cancer Inst 2008 Dec 17; 100 (24): 1763-70
41. Garau M, Shah KK, Mason AR, et al. Using QALYs in cancer: review of the methodological limitations. London: Office of Health Economics, 2010 Oct 26. Report no. 10/01
42. Sturza J. A review and meta-analysis of utility values for lung cancer. Med Decis Making 2010 Nov; 30 (6): 685-93
43. Barbieri M, Drummond M, Willke R, et al. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability. Value Health 2005 Jan; 8 (1): 10-23 (Pubitemid 40293637)
44. Anderson R. Systematic reviews of economic evaluations: utility or futility? Health Econ 2010 Mar; 19 (3): 350-64
45. Jack B, Boland A, Dickson R, et al. Best supportive care in lung cancer trials is inadequately described: a systematic review. Eur J Cancer Care (Engl) 2010 May; 19 (3): 293-301